Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024GlobeNewsWire • Monday
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/05/24
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisGlobeNewsWire • 09/03/24
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024GlobeNewsWire • 08/26/24
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/24
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)GlobeNewsWire • 07/17/24
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceGlobeNewsWire • 07/11/24
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)GlobeNewsWire • 07/10/24
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical TrialGlobeNewsWire • 06/25/24
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association CongressGlobeNewsWire • 05/28/24
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor ConferenceGlobeNewsWire • 05/23/24
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical MeetingGlobeNewsWire • 05/15/24
Unicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/24
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceGlobeNewsWire • 04/10/24
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/28/24
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association CongressGlobeNewsWire • 03/25/24
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT ConferenceGlobeNewsWire • 03/13/24
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)GlobeNewsWire • 03/07/24
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant PatientsGlobeNewsWire • 03/04/24
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingGlobeNewsWire • 02/14/24
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT ConferenceGlobeNewsWire • 01/29/24